A Safety Study of 188-0551 Spray Versus Reference Listed Drug (RLD) in Adult Subjects With Plaque Psoriasis
Status:
Completed
Trial end date:
2021-01-20
Target enrollment:
Participant gender:
Summary
Adrenal suppression effects of corticosteroids are among the most important safety concerns
for this group of products. This study is to determine and compare the adrenal suppression
potential and the pharmacokinetic (PK) properties of 188-0551 Spray versus an FDA-approved
drug (also known as a "Reference Listed Drug" [RLD]) under maximal use conditions when
applied twice daily (approximately every 12 hours) in adult subjects with stable, moderate to
severe, plaque psoriasis.